Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA/BE of ER Torsemide and Spironolactone FDC in Healthy Subjects
NCT07015671Phase 3Completed
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of torasemide and spironolactone in edema and hypertension (HTN) (4 arms). Primary endpoints: Bioequivalence and bioavailability of the FDC to each of its components at 27 days and Urinary torsemide excretion at 27 days. Started Jul 2025; status: completed.
02
Drugs
torasemidespironolactone
03
Conditions
edemahypertension (HTN)
Beyond the preview
Go deeper on NCT07015671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015671.